<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Methoxamine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00723</strong>&#160; (APRD00062)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00723/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00723/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00723.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00723.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00723.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00723.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00723.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00723">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>M&#233;thoxam&#233;drine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Methoxamin</td><td>German</td><td>INN</td></tr><tr><td>M&#233;thoxamine</td><td>French</td><td>INN</td></tr><tr><td>Methoxaminum</td><td>Latin</td><td>INN</td></tr><tr><td>Metossamina</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>DCIT</td></tr><tr><td>Metoxamina</td><td>Spanish</td><td>INN</td></tr><tr><td>Pseudomethoxamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Methoxamine Hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000971/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000971/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000971">DBSALT000971</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Mexan</td><td>Nippon Shinyaku</td></tr><tr><td>Vasoxine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Vasoxyl</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/vasoconstrictor-agents">Vasoconstrictor Agents</a></li>
<li><a href="/mesh/sympathomimetics">Sympathomimetics</a></li>
<li><a href="/mesh/adrenergic-alpha-1-receptor-agonists">Adrenergic alpha-1 Receptor Agonists</a></li></ul></td></tr><tr><th>CAS number</th><td>390-28-3</td></tr><tr><th>Weight</th><td>Average: 211.2576<br>Monoisotopic: 211.120843415</td></tr><tr><th>Chemical Formula</th><td>C<sub>11</sub>H<sub>17</sub>NO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>WJAJPNHVVFWKKL-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C11H17NO3/c1-7(12)11(13)9-6-8(14-2)4-5-10(9)15-3/h4-7,11,13H,12H2,1-3H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=CC(C(O)C(C)N)=C(OC)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenethylamines</td></tr><tr><th>Direct parent</th><td>Amphetamines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Anisoles; Alkyl Aryl Ethers; Secondary Alcohols; 1,2-Aminoalcohols; Polyamines; Monoalkylamines</td></tr><tr><th>Substituents</th><td>phenol ether; anisole; alkyl aryl ether; 1,2-aminoalcohol; secondary alcohol; ether; polyamine; amine; primary amine; primary aliphatic amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Indicated for the treatment and management of hypotension.</td></tr><tr><th>Pharmacodynamics</th><td>Methoxamine is a potent sympathomimetic amine that increases both systolic and diastolic blood pressure. Methoxamine is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. Methoxamine acts on both &#945;1-adrenergic receptors but appears to have no effect on &#946;-adrenergic receptors. It acts by increasing the force of the heart's pumping action as well as constricting peripheral blood vessels.</td></tr><tr><th>Mechanism of action</th><td>Methoxamine acts through peripheral vasoconstriction by acting as a pure alpha-1 adrenergic receptor agonist, consequently increasing systemic blood pressure (both systolic and diastolic).</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Low</td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9751</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.8857</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5637</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6457</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9698</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9823</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9217</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8341</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.6858</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6635</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9506</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8328</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8476</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.637
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8754
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9117
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.0534 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.951
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9331
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Glaxosmithkline</li></ul></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of methoxamine.</td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of methoxamine.</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of methoxamine.</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of methoxamine.</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of methoxamine.</td></tr><tr><td><a href="/drugs/DB01170">Guanethidine</a></td><td>Methoxamine may decrease the effect of guanethidine.</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of methoxamine.</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00601">Linezolid</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB00968">Methyldopa</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00211">Midodrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01171">Moclobemide</a></td><td>Moclobemide increases the sympathomimetic effect of methoxamine.</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of methoxamine.</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00206">Reserpine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Methoxamine. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Trimipramine may increase the vasopressor effect of the alpha1-agonist, Methoxamine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>